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Background: Approximately 10-30% of colorectal cancers are characterized with 
distinctly high densities of tumour-infiltrating lymphocytes (TILS), including CD3+, 
cytotoxic CD8+, activated cytotoxic CD8+/Granzyme B (GZMB)+, and regulatory T 
(Treg) FOXP3+ cells. High densities of TILS in CRC have been associated with good 
prognosis. However, it has been unclear whether the longer survival associated with 
TILS is due solely to the anti-tumour immune response, or whether this phenotype 
also responds better to adjuvant treatment. Furthermore, the propensity for certain 
CRC patients to have high TILS is not well-understood. 
Aims: This study aimed to: (i) evaluate the prognostic and predictive significance of 
TILS and its subtypes. (ii) assess the correlation between the densities of T cell 
subtypes in the peripheral blood and primary tumours in CRC patients; (iii) 
characterize the correlations between single nucleotide polymorphisms (SNPs) in 
CD8a, GZMB and FOXP3 genes in CRC patients and respective gene expression and 
T cell densities in peripheral blood and tumours. 
Methods: Tissue microarrays containing tumour samples from 439 CRC cases were 
immunohistochemically evaluated for the densities of CD3, CD8, Granzyme B 
(GZMB) and FOXP3-positive tumour-infiltrating lymphocytes. The prognostic 
significance of high CD3+, CD8+, CD8+GZMB+ and FOXP3+ cell density was 
evaluated in patients treated with surgery alone, while their predictive significance 
was estimated by comparing the survival of stage III patients treated with or without 
5-Fluorouracil (5-FU)-based chemotherapy. Matched peripheral blood samples and 
tissue sections from 50 CRC patients were analyzed for their T cell densities by flow 
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cytometry and immunohistochemistry respectively. SNPs in CD8a (n=12), GZMB 
(n=22) and FOXP3 (n=41) were genotyped by Sequenom MassARRAY iPLEX 
analysis, and examined for their correlation with respectively blood and tumour T cell 
densities and gene expression levels. 
Results: High densities of CD3+, CD8+, CD8+GZMB+ and FOXP3+ cells were 
associated with better overall survival (hazard ratios (HRs) of 0.57-0.67) in univariate 
(each P<0.05) analysis. Stage III patients with high CD3+, CD8+ and CD8+GZMB+ 
cell densities and treated with chemotherapy had a better survival than patients treated 
by surgery alone (HR= 0.18, 0.26 and 0.26, respectively; each P<0.01). Patients with 
low densities also had a better survival from treatment, but to a lesser degree (HR= 
0.55, 0.51 and 0.51, respectively; P=0.11, 0.05 and 0.06, respectively). The degree of 
inferiority was significant for CD3+ (P=0.032). Densities of each of the T cell 
subtypes in peripheral blood correlated with respective intra-tumour densities (all 
P<0.05). Eleven SNPs in blood and 3 in tumour samples were associated with 
respective T cell densities (P<0.05). The GZMB rs8192922 SNP was the only one 
associated with both blood and tumour densities, with higher densities of 
CD8+GZMB+ cells associated with the GG genotype. 
Conclusions: The improved prognosis of CRC patients with TILS may in part be due 
to a beneficial interaction between TILS and chemotherapy. CRC patients with TILS 
may have heightened circulating T cell densities compared to those without TILS. 
The GZMB rs8192922 GG genotype may be a related factor in these heighted 
densities. Taken together, the results suggest less invasive genetic and/or peripheral 
blood monitoring of TILS, and consequent prognostication and prediction of 5-FU 
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4 INTRODUCTION
4.1 Colorectal Cancer 
With almost one million new cases per year, colorectal cancer (CRC) accounts for 
9.4% of all new cancer cases worldwide (Parkin 2004). The rates of progress of 
industrialization and urbanization have paralleled the rates of CRC (Labianca et al. 
2010). During the period of 2003-2007, colorectal cancer was the first and second 
commonest cancers among Singaporean men and women, respectively. It was also 
one of the cancers with the highest mortality rate in both genders 
(SingaporeCancerRegistry 2003-2007). Older age, high intake of red meat, obesity 
and living with sedentary life style are factors that contribute to a high incidence of 
CRC in different degrees (Seow et al. 2002; Wong and Eu 2007).  
Surgery remains the primary treatment for stage I to III colon cancer and adjuvant 
chemotherapy is used to reduce the risk of relapse and death in stage II-IV patients. 
Currently, chemotherapy is recommended post-operatively in high-risk stage II 
(Midgley and Kerr 2005) and stage III patients. However, it is debatable whether 
chemotherapy is needed in stage II patients since they have a 80% chance of being 
relapse-free (Gray et al. 2007).  
Various clinicopathological and molecular parameters have been examined for their 
prognostic significance in CRC. Currently, TNM staging remains as the gold standard 
for prognosis. Other histopathological features such as vascular invasion, resection 
margin and tumour grade have also been well-studied for their associations with 
prognosis (Compton et al. 2000; Morris et al. 2006). Clinical parameters including 
obstruction and perforation at presentation (Steinberg et al. 1986), and pre-operative 
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carcinoembryonic antigen (CEA) levels (Wanebo et al. 1978) have been shown to 
have an independent influence on survival outcomes. In addition to histopathological 
and clinical factors, genetic alterations have been described to refine prognostic 
information and predict survival benefit derived from systemic treatment. The 
mutation status of KRAS (Andreyev et al. 1998; Andreyev et al. 2001) and APC 
(Lovig et al. 2002) and TP53 (Russo et al. 2005), loss of heterozygocity (LOH) of 
chromosome 18q (Alhopuro et al. 2005; Popat and Houlston 2005) and the CpG 
island methylator phenotype (CIMP) (Ogino et al. 2009) have been shown to be 
associatied with CRC patient survival outcomes. However, none of these markers is in 
routine clinical use and more effort is needed to validate their reliability and 
consistency. 
4.2 5-Fluorouracil-Based Chemotherapy 
The antimetabolite, 5-Fluorouracil (5-FU) is a pyrimidine analog that was designed 
and synthesized by Charles Heidelberger in 1957 (Heidelberger et al. 1957). It has 
been widely used for treating a range of cancers, including colorectal and breast 
cancers, and cancers of the aerodigestive tract (Longley et al. 2003). It principally acts 
as a thymidylate synthase inhibitor and can be converted intracellularly to several 
active metabolites such as fluorodeoxyuridine monophosphate (FdUMP), 
fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine triphosphate (FUTP) 
(Longley et al. 2003). These metabolites disrupt RNA and DNA synthesis as well as 
the action of thymidine synthase. This leads to cell cycle arrest and apoptosis through 
disruption of DNA synthesis. 
5-FU has been used for more than 40 years in the treatment of CRC, however, the 
overall response rate for 5-FU as a single agent in advanced CRC is only 10-15% 
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(Johnston and Kaye 2001). Therefore, important modulation strategies have been 
developed to increase the anti-cancer activity of 5-FU and prevent clinical resistance. 
The combination of 5-FU with other drugs including leucovorin, methotrexate 
(MTX), oxaliplatin and irinotecan have been studied to modulate the anti-cancer 
activity of 5-FU. For metastatic CRC, not all patients benefit from chemotherapy and 
are exposed to toxic or lethal effects unnecessarily in many cases (Gray et al. 2007).  
The presence of drug resistant micrometastic tumour cells are also likely to reduce the 
effectiveness of adjuvant chemotherapy following surgery (Longley et al. 2006). 
Characterization of the biological factors that correlate with response to 5-FU-based 
chemotherapy is crucial in defining patients who are most likely to benefit from the 
treatment. Molecular markers such as enzymes involved in 5-FU metabolism (Soong 
et al. 2008), CpG island methylator  phenotype (CIMP) status (Van Rijnsoever et al. 
2003) and microsatellite instability (MSI)  (Popat and Houlston 2005; Sinicrope et al. 
2006) have been associated with patient outcomes from chemotherapy in CRC. The 
validation of predictive markers not only helps to predict tumour and patient response 
to chemotherapy, but also permits selection of the best combined treatment for an 
individual patient (Longley et al. 2006). 
4.3 Adaptive Immunity in Cancer 
The definition and key concepts of „immune surveillance‟ were first established by 
Burnet and Thomas in 1960s (Burnet 1967).  Burnet believed that tumour cell-specific 
neo-antigens could provoke an effective immunologic reaction that would eliminate 
developing cancers (Burnet 1957; Burnet 1964; Burnet 1971). Alternatively, Thomas 
suggested that complex long-lived organism must possess a mechanism to protect 
against neoplastic disease similar to those involved in homograft rejection (Thomas 
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1959). However, the cancer immunosurveillance hypothesis only started to gain 
recognition after the ideas of Burnet and Thomas were supported by the functional 
demonstration of tumour-specific antigens in mice (Old and Boyse 1964).   
Accumulating reports have begun to elucidate the cellular basis of cancer 
immunosurveillance and demonstrate that lymphocytes of both innate and adaptive 
immune compartments prevent tumour development (Dunn et al. 2004). Studying 
activation of dentritic cells (DCs) by  endogenous signals (Matzinger 1994; Gallucci 
et al. 1999; Gallucci and Matzinger 2001) and their interaction with cytotoxic T 
lymphocytes (CTLs) (Ridge et al. 1996; Bennett et al. 1998; Schoenberger et al. 
1998), Smyth et al. proposed a model of adaptive immune response to tumour-derived 
tumour-associated-antigens (TAA) in melanoma (Smyth et al. 2001). „Danger‟ signals 
such as cytokines or heat shock proteins (HSPs) (Gallucci et al. 1999; Gallucci and 
Matzinger 2001) that are released by cells undergoing damage and necrotic death 
cause activation of antigen-presenting DCs. Once activated, DCs initiate and control 
an adaptive immune response toward tumour-associated-antigens (TAAs). TAAs, 
processed and presented by major histocompatibility class (MHC) class I and class II 
molecules on a single DC, then enable priming and activation of both CD4+ T cell 
and CD8+ T cells (Ridge et al. 1996; Bennett et al. 1998; Schoenberger et al. 1998). 
Ultimately, activated antigen-specific CD8+ T cells differentiate into CTLs and 
destroy tumour cells (Figure 1).  
How chemotherapy could modulate the host immune system in cancer patients is still 
not fully elucidated. Although the actions of different chemotherapeutic drugs vary, 
their effects on cancer cells are similar (Lake and van der Most 2006). Animal 
experiments conducted by Casares et al. showed that after the lethal effects of 
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chemotherapy, the apoptotic cancer cells become more „immunogenic‟, and can excite 
the immune system (Casares et al. 2005). This event stimulates a second wave of cell 
killing via the adaptive immune response that can further improve the outcome from 
chemotherapy (Figure 2) (Lake and van der Most 2006). In contrast, Shankaran et al. 
(Shankaran et al. 2001) has shown that the immune system may also promote the 
emergence of primary tumours with reduced immunogenicity that are capable of 
escaping immune recognition and destruction. This is known as immunoediting. 
Tumour immunity, which initially provides host protection from cancer may 
ultimately drive the generation of tumours better suited to survive in an 
immunologically intact environment (Dunn et al. 2004). 
Undoubtedly, improved understanding of the immunobiology of cancer 
immunosurveillance and immunoediting will help in developing immunotherapy to 
control and/or eradicate neoplastic disease in cancer patients (Dunn et al. 2004). 
4.4 Tumour Infiltrating Lymphocytes (TILS) And Subtypes  
4.4.1 Phenotypic and functional characteristics of TILS, Regulatory T cells 
(Tregs) and cytotoxic T cells (CTL) 
Cancers are commonly infiltrated by immune cells along their invasive margin. The 
most frequent cell types are T and B lymphocytes and a minority are dendritic cells, 
natural killer cells and macrophages (Ohtani 2007). The anti-tumour activity of these 
cells has been well established in pre-clinical models, making it highly plausible that 




Figure 1. The adaptive immune response to tumour-derived TAAs such as MAGE1 
and MART1 in melanoma.  
One of the earliest steps toward mounting an adaptive response to TAAs is the capture 
and presentation of these molecules by professional APCs such as DCs. Additionally, 
to present costimulatory molecules, such as B7, to T lymphocytes, APCs must be 
activated by danger signals. In conjuction with costimulation (for example, B7-CD28 
interaction), activated APCs carry TAAs to lymph nodes where the TAA-derived 
peptides are presented via MHC class II molecules to CD4+ and MHC class I 
molecule to CD8+ T lymphocytes. Stimulated CD4+ T cells subsequently express 
CD40L, which, in turn, further stimulates CD40-expressing APCs. B lymphocytes 
(not shown) are also likely to be involved in this immune response. TAA-specific 
lymphocytes develop into activated effector cells—CD8+ CTLs and CD4+T helper 
cells—with the ability to migrate into the tissue to mount an attack against the 
developing melanoma. This is likely to involve both CD4+, CD8+ T cells and local 
APCs (possibly B cells, macrophages and DCs). APC, antigen-presenting cell; CTL, 
cytotoxic T lymphocyte; DC, dendritic cell; HSP, heat shock protein; TH, T helper 
lymphocyte. (Adapted from Smyth et al. 2001) 
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Figure 2. Harnessing the immune system to kill cancer cells.  
 
Cancer cells that die after treatment with cytotoxic agents can be processed by 
dendritic cells for presentation to CD4+CD8+ T cells. Some drugs initiate a program 
of targeting and killing cells that amplifies this process. Dying cells then express 
molecules that serve as danger signals (yellow box) that activate dendritic cells to 
prevent cancer antigens in an inflammatory context. In response, dendritic cells up-
regulate costimulatory molecules and secrete cytokines such as interleukin-12. 
Immunotherapies that target dendritic cells (blue box) may induce an effective 
immune response even if danger signals are not expressed by dying tumour cells. 
Additional immunotherapies directed at T cells (red box) may also promote 
antitumour immunity. (Adapted from Lake and van der Most 2006) 
 8 
The major T lymphocyte subtypes within TILS can be identified by distinctive 
cellular markers. CD3 total T lymphocytes play a central role in cell-mediated 
immunity and they can be classified into several different subsets of T cells with 
distinct functions. The most commonly discriminated types include CD8+ cytotoxic 
cells, CD4+ effector cells and CD45RO+ antigen sensitized memory T cells. Also 
included are CD4+/CD25+/FOXP3+ and  CD8+/CD25+/FOXP3+ regulatory cells, 
referred to as T4regs and T8regs respectively.  
Cytotoxic T cells are also known as killer T cells because of their capability to induce 
the death of infected, damaged, or dysfunctional cells. In general, cytotoxic T cells 
express the glycoprotein CD8, and can recognize specific antigen peptides bound to 
class I major histocompatibility complex (MHC) molecules. The activation of CTL 
requires at least two simultaneous interactions between receptors expressed on the 
surface of T cells and ligands on the surface of antigen-presenting cells (APC). The 
first signal is provided by the interaction of the T cell receptor of CTL with a specific 
antigen that is presented on the surface of the APC. The second signal is a co-
stimulatory signal which is mediated by interactions between CD28 of CTL and 
costimulators (such as CD80 or CD86) which are expressed on the APC. Once CTLs 
are activated, they are highly cytolytic and able to induce death through releasing 
perforin and enzyme proteases (granzymes) or Fas-FasL interaction. 
Regulatory T cells were first discovered in 1970 (Gershon and Kondo 1970). Since 
then, the physiological and pathological role of Tregs in mouse and man have been 
widely studied. Some Tregs derive from the thymus and are known as “natural Tregs” 
(nTregs) (Sakaguchi et al. 1995), whereas other T cells that have been induced to 
become Tregs (iTregs) in peripheral lymphoid organs (Bluestone and Abbas 2003). 
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Treg cells are known as a minor population of CD4+ T cells expressing CD25 and the 
alpha subunit of interleukin 2 (IL-2) receptor (Sakaguchi et al. 1995). However, these 
markers were found to also be abundantly expressed on activated T cells. In 2003, the 
fork head box transcription factor FOXP3 was identified as a bona fide marker of 
Tregs and its expression is crucial for regulatory activity (Fontenot et al. 2003). In 
addition to CD4 Treg cells, regulatory CD8 T cells (CD8 Treg) have also been 
identified and suggested to play an important role in immune tolerance (Ciubotariu et 
al. 1998; Liu et al. 1998; Kumar and Sercarz 2001; Field et al. 2003).  
Treg cells can inhibit the function of antigen-presenting cells or other cells of the 
innate immune system through four mechanisms: (i) secretion of suppressor cytokines 
(eg. IL10, TGF-b, IL-35 etc.) that can directly inhibit the function of responder T cells 
and myeloid cells;  (ii) induction of high expression of CD25 on the activated Treg 
cell surface, which has the capacity to compete with effector T cells for IL-2, leading 
to Bim-mediated effector T cells apoptosis; (iii) expression of  galectin-1 on activated 
Treg cells, which can interact with effector T cells and lead to their cell cycle arrest; 
(iv) direct killing of effector cells in a CD8+ cytotoxic cell-like manner by activated 
FOXP3+Treg cells (Shevach 2009).  
4.4.2 Prognostic Significance 
High levels of TILS are associated with favourable prognosis in several cancer types 
including breast (Marrogi et al. 1997), ovarian (Zhang et al. 2003), mesothelial (Leigh 
and Webster 1982) and colorectal cancer (Ropponen et al. 1997; Naito et al. 1998; 
Guidoboni et al. 2001; Menon et al. 2004; Prall et al. 2004).  
CD8+ T cells or the activated CTLs have been shown as a predictor for improved 
survival in breast (Guo et al. 2008), gastric (Lee et al. 2008), liver (Gao et al. 2007), 
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lung (Kawai et al. 2008), melanoma (van Houdt et al. 2008) and ovarian cancer (Sato 
et al. 2005; Callahan et al. 2008; Leffers et al. 2009). In CRC, infiltrating CD8+ cells 
in the cancer nest have been reported to be significantly associated with better 
survival and possess higher cytotoxic and proliferative activity than those in the 
stroma and invasive margins (Naito et al. 1998). CD8+ T cells have also been 
associated with microsatellite instability (MSI) in CRC tumours (Guidoboni et al. 
2001; Prall et al. 2004; Salama et al. 2009). Numerous mutations that occur in the 
MSI tumours lead to production of potentially immunogenic epitopes and 
subsequently induce CTL priming and cytotoxic activity.  
High infiltration of Treg cells has been associated with poor prognosis or high cancer 
recurrence in various cancer types such as melanoma (Miracco et al. 2007), breast 
(Bates et al. 2006), ovarian (Curiel et al. 2004; Sato et al. 2005), hepatocellular (Gao 
et al. 2007; Kobayashi et al. 2007) and pancreatic cancers (Hiraoka et al. 2006). In 
contrast, a better survival for CRC patients with high intra-tumoural Treg has been 
reported (Salama et al. 2009; Correale et al. 2010; Frey et al. 2010). This suggests 
that Treg cells may act as homeostatic controllers of a robust immune response 
instead of immunosuppressors in CRC (Matera et al. 2010).   
4.4.3 Predictive Significance 
Chemotherapy can induce a second round of massive tumour cell death by increasing 
antigen release and up-regulating immunogenic surface molecules on apoptotic 
tumour cells (Lake and Robinson 2005). High density of TILS was found to predict 
survival benefit from 5-fluorouracil-based (5-FU) adjuvant chemotherapy in stage III 
colon cancer patients (Morris et al. 2008). The percentage of intra-tumoural 
lymphocytes was also shown to be a significant parameter for complete pathologic 
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response in breast tumours treated with anthracycline-based neoadjuvant therapy 
(Denkert et al. 2010). These clinical observations support the notion that conventional 
cytotoxic chemotherapy can be a potent activator of pre-existing antitumour immune 
responses in cancer (Lake and van der Most 2006).  
In the phase II trial of a chemoimmunotherapy regimen, which combined 
gemcitabine, oxaliplatin, levofolinic acid, 5-FU, granuclocyte macrophage colony-
stimulating factor and interleukin 2 (GOLFIG-1), patients who received the treatment 
were found to have increased level of CTL in their peripheral blood (Correale et al. 
2008). In a murine study, treatment with gemcitabine results in increased antigen 
cross-presentation and priming of tumour-specific CD8 cells.  
Tregs have been found to be sensitive to chemotherapy. Low-dose oral 
cyclophosphamide in patients with advanced breast cancer selectively depleted the 
Treg subset and enhanced the cytotoxic capacity of T and natural killer cells (Diaz-
Montero et al. 2009). Similarly, circulating Tregs were greatly reduced in breast 
cancer and CRC patients who received anthracycline-based regimen (Ladoire et al. 
2008) and GOLFIG (Correale et al. 2008) respectively.  
4.5 Circulating immune cells 
The immune system is made up of a network of cells, tissues and organs that work 
together to protect the body. Hence, host response in tumours may also be reflected in 
other counterparts such as peripheral blood, peritoneal cavity, bone marrow or lymph 
node. Higher frequencies of T4reg (Clarke et al. 2006; Ling et al. 2007; Ahmadzadeh 
et al. 2008) and T8reg cells (CD8+FoxP3+) (Chaput et al. 2009) were observed in 
peripheral blood of cancer patients compared to healthy individuals. This has 
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suggested that the activation of immune response may possibly be systemic than 
localized in tumours.  
Peripheral immune cells were also found to be associated with clinical response to 
chemotherapy in CRC patients (Lissoni et al. 2006; Correale et al. 2008). Lissoni et 
al. reported an increase in the total peripheral blood lymphocyte count in patients who 
showed clinical response to chemotherapy with 5-FU and oxaliplatin, but a decrease 
in those who showed stable or progressive disease (Lissoni et al. 2006). However, 
studies on the prognostic and predictive values of peripheral blood cells are still 
preliminary. 
4.6 Single Nucleotide Polymorphism (SNP) 
A single nucleotide polymorphism (SNP) is defined as a change in a single nucleotide 
when alleles are compared. It occurs every ~1330 bases in the human genome (Lewin 
2004). SNP can be found within coding sequences of genes, non-coding regions of 
genes, or in the intergenic regions between genes.  When SNPs occur in the coding 
region of a gene, they may produce the same polypeptide sequence (also known as 
synonymous change) or different polypeptide sequence (non synonymous change). A 
non-synonymous change may be either missense or nonsense that leads to different 
amino acid or premature stop codon respectively. For SNPs that are not in the protein-
coding regions, they may still contribute to changes in gene splicing, transcription 
binding or affect the transcription of non-coding RNA.  
The immune system has the most complex task of responding to evolving 
environmental components that enter the organism through different routes in the 
form of pathogens (Jin and Wang 2003). Under this pressure, immune related genes 
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such as major histocompatibility complex (MHC), cytokines and toll-like receptors 
have been found to be polymorphic (Jin and Wang 2003; El-Omar et al. 2008). 
Inevitably, polymorphisms in immune-related genes can be associated with risk of 
infectious diseases (Kang and Chae 2001), allergy (Yang et al. 2004), cardiovascular 
disease (Girnita et al. 2009) and cancer (El-Omar et al. 2000; Sun et al. 2005; Hold et 
al. 2007).  
A variety of commercial platforms are developed to tailor for semi-automated or fully 
automated SNP genotype analysis (Table 1) (Ding and Jin 2009). Basically, the 
chemistry for SNP genotyping can be classified to two types: non-enzymatic 
differential hybridization and enzymatic reaction. Differential hybridization relies on 
different melting temperatures for matched and mismatched oligonucleotides binding 
to the target DNA sequences. Enzymatic reaction methods, two types of assays using 
incorporation of fluorescent nucleotides, and extension of product molecular weight 
have been developed. In general, differential hybridization based platforms rely 
entirely on hybridization thermodynamic differences between matched and 
mismatched pairing of probes and targets. Therefore, the probes must be effective in 
differentiating matched and mismatched targets. For enzymatic selectivity based 
platforms are less dependent on SNP local sequences, provide less background noise 
and allow for more SNPs detection (Ding and Jin 2009). 
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Table 1. Comparison of high throughput genotyping platforms.  
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4.7 Scope of Study 
The overall aims of the study were to understand the clinical relevance of adaptive 
immunity in CRC tumours. We first evaluated the prognostic (survival) and predictive 
(response to chemotherapy) value of tumour-infiltrating lymphocytes (TILS) subtypes 
in CRC tumours. Secondly, we examined the correlation between the circulating 
lymphocytes (blood) and TILS of CRC patients and screened for SNPs of T cell 
markers that may significantly associate with T cell densities. The specific aims were: 
Specific Aim 1: To characterize both the prognostic and predictive values of various 
tumour-infiltrating T-lymphocyte subtypes in CRC patients receiving 5-FU-based 
chemotherapy.   
Hypothesis: CRC patients with low Tregs densities and high cytotoxic T cell 
densities will be more responsive to chemotherapy. 
Specific Aim 2: To assess the correlation between the densities of T cell subtypes in 
the peripheral blood and primary tumours of CRC patients. 
Hypothesis: Individuals with high levels of circulating T cells are the individuals that 
exhibit TILS. 
Specific Aim 3: To characterize the correlations between SNPs in CD8a, GZMB and 
FOXP3 genes in CRC patients and respective gene expression and T cell densities in 
peripheral blood and tumours. 
Hypothesis: TILS and high circulating immune cells could be a manifestation of 
genetic differences that encode a heightened immune system.  
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5 MATERIALS AND METHODS 
5.1 Workflow 
A workflow of the study methods is given below in Figure 3. 
5.2 Cases and Tissue Arrays 
Tissue microarrays (TMA) containing cores from 439 routinely fixed and processed 
primary tumour specimens were obtained from consecutive patients who underwent 
surgical resection for histologically proven CRC at the National University Hospital 
of Singapore between 1990 and 1999. Details of the TMA construction and relevant 
patient data including the use of adjuvant chemotherapy with 5-FU-based regimens 
have been described previously (Ong et al. 2010). The available clinical and 
pathological information included gender, age, tumour size, tumour stage (AJCC), 
histological grade, vascular invasion, perineural invasion, and lymphatic invasion. 
Survival time was measured from the initial date of diagnosis until the date of cancer-
specific death, or censored at the time of last follow-up if the patient was still alive, 
lost of follow-up or had died of other causes. Some 99 cases were alive, 212 died 
from CRC, 88 died from other causes and 40 were lost of follow-up. Patients were 
selected to receive adjuvant chemotherapy based on age, the presence of “poor” 
prognosis features and patient/doctor preference in the course of routine clinical 
practice. Cases treated with chemotherapy underwent intravenous injection with 5-
fluorouracil (5-FU) using the Mayo regimen. One complete cycle of treatment 
involved dose administration ranging from 500 to 900 mg/m
2
/day for 3 to 5 
consecutive days. Each cycle was repeated monthly for 6 months or until progression 
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of disease, patient refusal or adverse reactions to the treatment. 
  18 
 
Figure 3. Overview of study workflow. 
IHC, immunohistochemistry; Ariol, automated slide imaging platform; MNC, mononuclear cells. 
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To assess the correlations of the densities of T cell subtypes between the matched 
peripheral blood and primary tumours, fifty CRC patients were recruited from 
National University Hospital (NUH) Department of Surgery and Haematology 
Oncology between 2008 and 2010. Blood samples from these patients were drawn 
before surgery. None of the patients had pre-operation radiotherapy or chemotherapy. 
A total of 7ml of peripheral blood was drawn into Vacutainer CPT tubes (Becton 
Dickinson, USA) and mononuclear cells (MNC) were collected after centrifugation at 
2500 rpm for 20min. MNCs were washed once with 6ml Roswell Park Memorial 
Institute medium (RPMI) supplemented with 10% fetal bovine serum (FBS) before 
re-suspending in 2.4ml freezing medium (40% RPMI, 50% FBS, 10% DMSO). 
MNCs were kept in cryovials and stored in -80°C for 24 hr and thereafter liquid 
nitrogen for long-term storage. Corresponding patient paraffin embedded tumour 
samples containing >50% tumour cells were collected from NUH Department of 
Pathology. Sections of 4-µm thickness were used for immunohistochemical staining. 
The protocol for this study was approved by the Institutional Review Board of the 
National University of Singapore (NUS-IRB reference code: 09-429). 
5.3 Immunohistochemistry 
Consecutive TMA and full face paraffin sections of 4μm thickness were cut and 
placed onto silanated slides for immunohistochemical detection of various T-
lymphocyte markers using a Bond-Max autostainer (Leica Biosystems, Newcastle, 
UK). For single staining of CD3 and FOXP3, heat-induced antigen retrieval with 
epitope retrieval ER1 solution (Leica Biosystems) was performed for 20 min prior to 
incubation with primary antibody. Slides were incubated with CD3 (Novocastra, 
Clone LN10, dilution 1:100) or FOXP3 (Abcam, clone 236/E7, dilution 1:250) at 
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room temperature (RT) for 15 min. After incubation, slides were washed three times 
with 1x Bond washing buffer (Leica Biosystems) and incubated with secondary 
antibody (Bond Polymer Refine kit, Leica Biosystems) for 8 min at room temperature. 
Chromogenic detection was achieved by incubation with 3,30-diaminobenzidine 
(DAB) for 10 min, followed by 5 min incubation with Bond DAB enhancer.  
For the double staining of GZMB/CD8 and CD4/FOXP3, heat-induced antigen 
retrieval with epitope retrieval ER2 solution (Leica Biosystems) was performed for 20 
min prior to incubation with primary antibody. Anti-GZMB (Novocastra, clone 11F1, 
dilution 1:40) or anti-FOXP3 (Abcam, clone 236/E7, dilution 1:250) antibodies were 
incubated for 30 min or 15min respectively at RT and then detected using the DAB 
chromogenic method described above. The slides were subsequently incubated with 
anti-CD8 antibody (DakoCytomation, clone 144B, dilution 1:600) or anti-CD4 
antibody (Novocastra, clone 4B12, dilution 1:50) and secondary antibody from the 
Bond Polymer Alkaline Phosphatase Red detection kit (Leica Biosystems) to give a 
distinct red stain with DAB staining. Negative controls comprised the omission of 
primary antibody, while internal positive controls for the immune cell markers were 
provided by lymphoid follicles present in adjacent normal colonic mucosa. 
All slides were counterstained with haematoxylin and dehydrated through ascending 
ethanol to Histo-Clear solution (National Diagnostics, Atlanta, GA) before mounting. 
Slides were scanned with a high resolution scanner (Ariol SL-50, Applied Imaging, 
San Jose, CA) at 100X and 400x magnifications. For TMA, the number of positively 
stained lymphocytes in the intraepithelial and stromal areas was counted by visual 
observation for each core and the density of lymphocytes for each tumour was then 
expressed as cells per square millimeter as described previously (15). For full face 
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paraffin sections, five regions (1mm
2 
each) with the highest infiltration of CD3 
positive lymphocytes were marked by pathologist. The positively stained cells were 
counted and the cell densities were determined by taking the average of the 5 regions. 
Scoring was performed by two observers (CPY and BT) without prior knowledge of 
patient characteristics. Inter-observer agreement was greater than 0.837 for the stains 
by the Kappa test.  
5.4 Microsatellite Instability Analysis 
Tumour blocks corresponding to 278 cases in the tissue array were retrieved from 
Pathology archives. Three 8µm sections were cut from each block, and DNA was 
extracted using the Gentra Purgene Tissue kit (Qiagen, Hilden, Germany). 
Microsatellite instability was determined by analysis of 5 mononucleotide repeats, 
including BAT-25, BAT-26, NR21, NR22, NR24 and NR27, as reported by Buhard et 
al. (Buhard et al. 2006). Tumours were defined as MSI when ≥3 markers showed 
instability. 
5.5 Flow Cytometry 
Frozen MNCs were quickly thawed in 37°C water bath. Cells were washed with 5ml 
RPMI supplemented by 10% Fetal Bovine Serum (FBS) followed by 5ml of staining 
buffer (phosphate-buffered saline [PBS] with 3% FBS). Cells were then spun at 
1200rpm for 5min. The pellets were re-suspended in 100μl of cold staining buffer and 
stained with antibodies against surface antigens (CD3 and CD4 or CD8) for 30min in 
the dark at 4°C. Cells were subsequently washed in staining buffer twice prior to 
fixation. For FOXP3 and GZMB, cells were permeabilized using the Foxp3 Staining 
Buffer Set (eBioscience, San Diego, CA) according to the manufacturer‟s 
instructions. Negative controls comprised the omission of antibodies against surface 
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markers and allophycocyanin-conjugated isotype control antibody of anti-FOXP3 
(eBioscience) or anti-granzyme B (Invitrogen) only. All the dilutions of antibodies 
were according to the manufacturers‟ recommendation. 
Stained cells were analyzed on FACS LSRII flow cytometry instrument (BD 
Bioscience, San Jose, CA) and data were analyzed using FlowJo software (TreeStar, 
Ashland, OR). Quadrants were set based on negative controls. The information for the 
antibodies mentioned above and their dilutions used are listed in Table 2. The cell 
densities were expressed as percentage of positive cells of total CD3+ T cells.  
Table 2. Antibodies and dilutions used for flow cytometry.  
 
5.6 DNA and RNA Extraction  
Frozen MNCs were quickly thawed in a 37°C water bath. Cells were washed with 5ml 
of PBS and centrifuged at 5,000 rpm for 2 min at 4°C. Trizol (Invitrogen, Carlsbad, 
CA) was used to extract total RNA and DNA from the cell pellets according to 
manufacturer‟s instructions. The yields and purity of RNA and DNA were determined 
spectrophotometrically at 260nm and 280nm using a Nanodrop (Thermo Scientific, 
Wilmington, DE).  
Antibody Manufacturer Clone Fluorochrome Vol. used (μl) 
     
Treg markers    
CD3 BD SK7 APC-Cy7 20 
CD4 BD RPA-T4 FITC 20 
FOXP3 eBioscience PCH101 APC 5 
     
Cytotoxic T cell markers    
CD3 BD UCHT1 FITC 20 
CD8 eBioscience RPA-T8 PE-Cy7 5 
Granzyme B Invitrogen GB12 APC 5 
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5.7 Gene expression analysis 
A total of 0.5μg of total RNA was treated with (RNAse-free) DNAse I (New England 
Biolabs, Ipswich, MA) for 10min at 37°C. DNAse I activity was inactivated by 
adding EDTA and heating at 75°C for 10min. The integrity of RNA was determined 
by the ratio of 28S and 18S values using Bioanalyzer (Agilent Technologies, Santa 
Clara, CA) with the RNA 6000 Nano kit. A total of 250ng of DNAse-I treated RNA 
was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Inc., Foster City, CA). The reaction mixtures were incubated at 
25°C for 10 min, then 37°C for 120 min and 95°C for 5 min.  
The expression of CD8a (Hs00233520), GZMB (Hs01554355), FOXP3 
(Hs01085834) and ACTB (Hs99999903) was analyzed by real time PCR (QPCR) 
using TaqMan
® 
custom gene expression assays (Applied Biosystems). All reactions 
were performed in 20 μL reactions, in duplicate within the same PCR run. Negative 
controls consisting of the addition of water for each gene target analyzed were 
included in each PCR. For each well 1μl of cDNA (equivalent to 12.5ng of RNA) 
from each sample was added to 20μl of PCR reaction mix consisting of 10× 
TaqMan® Fast Universal PCR Master Mix (Applied Biosystems, Foster city, CA) 
and 1μl gene expression assay primer-probe mix. PCR was initiated with a 10 minute 
incubation at 95°C followed by 40 cycles of 95°C for 15 seconds and 60°C for 60 
seconds, in accordance with the manufacturer's recommendations. Real-time PCR and 
relative quantification were performed using an ABI PRISM 7900 HT Sequence 
Detection System (Applied Biosystems). The expression values of target gene were 
normalized to ACTB levels using SDS 2.2.1 software (Applied Biosystems). 
 
  24 
5.8 Genotyping 
SNP genotyping in clinical samples were carried out using the MassArray iPLEX 
genotyping platform (Sequenom, San Diego, CA) according to manufacturer‟s 
instructions. SNPs, consisting of 10 in CD8a, 22 of GZMB and 7 of FOXP3 (Table 8) 
with a minor allele frequency (MAF)≥1% were selected from the dbSNP database. 
Three assays comprising 19, 17 and 3 multiplex PCRs respectively were designed 
using both the MassArray Assay Design 4.0 and MassArray Online Design Tools 
(Sequenom). PCR amplification was carried out using 20ng of DNA in a 5µl reaction 
that contained 0.5U Taq polymerase, 10X PCR buffer, 4mM MgCl2, 500µM dNTPs 
and 0.1µM of primers. The following program was used for PCR amplification: 95
o
C 
for 2 minutes, followed by 45 cycles of 95
o
C for 30 seconds, 56
o
C for 30 seconds, 
72
o
C for 1 minute and a final extension step of 72
o
C for 5 minutes. Unincorporated 
dNTPs were removed using 0.3U shrimp alkaline phosphatase dissolved in the SAP 
buffer provided. Single-base extension was carried out in a 9µl reaction that contained 
iPLEX GOLD buffer, iPLEX termination mix, iPLEX extend primer mix and iPLEX 
enzyme. The reactions were performed using the following two cycling loop 
programs: initial denaturation was for 30s at 94°C followed by five cycles of 5s at 
94°C, 5s at 52°C and 5s at 80°C. An additional 40 annealing and extension cycles 
were then looped back to 5s at 52°C and 5s at 80°C. The final extension was carried 
out at 72°C for 3min, before cooling to 4°C. Reactions were desalted using 6 mg 
clean resin and diluted with 16µl water. 10nl of each reaction was spotted onto the 
384-spot SpectroChipII using the Nanodispenser. This was followed by matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry analysis using 
the MassARRAY Compact system. Spectra analysis and genotype calls were 
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generated using the TYPER 3.3 software (Sequenom). 
5.9 Statistical Analysis 
T-lymphocyte densities were classified as high or low relative to the median value. 
Chi-square analysis was used to examine for possible non-random associations 
between T-lymphocyte densities and clinicopathological features. Univariate Cox 
proportional hazards analysis was used to determine the prognostic significance of 
various clinicopathological features and T-lymphocyte subtype densities. Multivariate 
analysis was performed by Cox regression analysis (Method = “Enter”) using the 
factors identified to be significant in univariate analysis. Predictive significance was 
determined by comparing the survival of patient groups treated with or without 5-FU 
chemotherapy in respective patient subgroups of interest. Differences in hazard ratios 
were assessed using the hr.comp function under the survcomp library in R (The R 
Foundation for Statistical Computing).  
Associations between T cell densities in peripheral blood and tissue were determined 
by Pearson correlation coefficient. The same statistical method was also used to 
assess the correlation between the gene expression levels of the T cell markers and 
their corresponding cell densities in peripheral blood. Chi-square test with case 
weighting applied was applied to assess the difference between SNP distributions in 
the NUH cohort and other reported Asian cohorts. Chi-square test was also used to 
assess the associations between SNPs and the T cells densities in blood and tissue. T 
cell densities were dichotomized by median.  
Significance was set at the 5% level and no corrections were made for multiple 
comparisons. Unless otherwise mentioned, statistical analyses were performed using 
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the SPSS package version 18.0 for Windows (SPSS, Chicago, IL). 
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6  PROGNOSTIC AND PREDICTIVE SIGNIFICANCE 
OF TILS SUBTYPE DENSITIES IN CRC  
6.1  Introduction 
Cancers are frequently infiltrated by immune cells along their invasive margin. The 
most frequent cell types are T and B lymphocytes, however the infiltrates also include 
dendritic cells, natural killer cells and macrophages (Ohtani 2007). The anti-tumour 
activity of tumour-infiltrating lymphocytes (TILS) has been well established in pre-
clinical models, making it highly plausible that immune cell density, type and 
function could affect the clinical phenotype of tumours. Indeed, one of the most 
reproducible findings in prognostic studies has been that a high density of tumour-
infiltrating lymphocytes (TILS) is associated with improved patient survival. In 
colorectal cancer (CRC) alone, at least 15 independent reports on the prognostic value 
of TILS have provided very consistent results (Broussard and Disis 2011). Similar 
findings have been reported for breast, prostate and small cell lung cancers. In many 
cases, the association has been independent of tumour staging, prompting some 
investigators to suggest this feature may even provide superior prognostic information 
to the TNM system in CRC (Pages et al. 2005; Galon et al. 2006; Mlecnik et al. 
2011). 
Nonetheless, an unresolved issue is whether an interaction between immune cells and 
chemotherapy could also be contributing to the better survival of patients with high 
levels of TILS. Cytotoxic treatment can destroy tumour cells by inducing necrosis, 
thus leading to the release of cytokines which can in turn activate cytotoxic T-
lymphocytes at the tumour site (Lake and Robinson 2005). This event stimulates a 
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second wave of cell killing via the adaptive immune response that could further 
improve the outcome from chemotherapy. In support of this, we previously reported 
that the survival difference of patients treated with chemotherapy compared to those 
untreated was greater if the patients had a high compared to low TILS density (Morris 
et al. 2008). The density of immune cells in the primary tumour was also found to 
correlate with the response to chemotherapy in a study of metastatic CRC (Halama et 
al. 2009). In breast cancer, the presence of intra-tumoural lymphocytes was found to 
be a significant predictor for complete pathological response to neoadjuvant 
chemotherapy (Ladoire et al. 2008; Denkert et al. 2010).  
TILS consist of many different subtypes, some of which can be readily identified by 
immunohistochemical staining for distinctive cellular markers. Anti-tumourigenic 
total, cytotoxic, activated cytotoxic and regulatory T-lymphocytes are identified by 
the expression of CD3, CD8, CD8/Granzyme B (GZMB) and FOXP3, respectively. 
The first three markers are linked to anti-tumour activities (Rosenberg 1996; 
Chowdhury and Lieberman 2008). FOXP3+ T-lymphocytes are postulated to suppress 
the activity of cytotoxic T-lymphocytes through direct cell-to-cell contact and through 
the release of cytokines, especially transforming growth factor-β (Clarke et al. 2006). 
With these contrasting activities, it is plausible that the observed prognostic and 
predictive values of TILS may differ according to the specific cell subtype. In the 
present study we examined these attributes for CD3+, CD8+, CD8+GranzymeB+ 
(GZMB+) and FOXP3+ cell densities in a cohort of 439 CRC patients for which 
extensive pathological and clinical information was available. 
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6.2 Results 
6.2.1 Density and Cinicopathological Associations of T-lymphocyte subtypes in 
CRC 
Representative images of single immunohistochemical stains for CD3 and FOXP3 
and double stains for CD8/GZMB are shown in Figure 4. Activated cytotoxic T-
lymphocytes were identified as cells that co-expressed CD8 at the cell surface and 
GZMB in the cytoplasm (Figure 4E). FOXP3 staining was observed exclusively in the 
nucleus of lymphocytes (Figure 4F). The distribution of cell densities for the different 
T-lymphocyte markers is provided in the Figure 5. The densities of all subtypes were 
significantly correlated to each other (Figure 6). Although FOXP3 staining is thought 
to represent T regulatory cells, positive correlations were seen with the densities of 
CD3+, CD8+ and CD8+GZMB+ cells. Associations between T-lymphocyte subtype 
densities and standard clinicopathological features for CRC are shown in Table 3. 
Early stage tumours (AJCC stage I and II) more often displayed high densities of the 
T-lymphocyte subtypes compared to late stage tumours (P<0.01 for each marker). 
With the exception of perforation and FOXP3+ cell density, no significant 
associations were seen between the other clinicopathological features and T-
lymphocyte marker densities. Microsatellite instability (MSI) status was analyzable in 
278 tumour samples, of which 31 (11%) had MSI. MSI tumours had higher densities 
of CD8+ (P=0.04) and CD8+GZMB+ T cells (P<0.01). 
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Figure 4. Immunohistochemical stains for CD3 (A, D), double staining of CD8 and 
GZMB (B, E), and FOXP3 (C, F).  
In (E), the filled arrow (E) highlights an activated cytotoxic T lymphocyte with co-
expression of CD8 (red) and GZMB (brown). The unfilled arrow highlights a 
cytotoxic T cell with no GZMB expression. Magnification for figure A-C: 100x; 
Magnification for figure D-F: 400x. Brown and red stains were achieved by 
incubation with DAB and alkaline phosphatase red respectively; and the nuclei were 
counterstained with haematoxylin. 
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Figure 5. Density of respective T-lymphocyte subtypes detected by 
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Figure 6. Correlation between T-lymphocyte subtype densities in CRC 
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P  CD8+ 
High (%) 
P  CD8+GZMB+ 
High (%) 
P  FOXP3+ 
High (%) 
P 
            
Age            
  <60 years (125) 64 (51.2)   66 (52.8)   66 (52.8)   59 (47.2)  
  ≥60 years (314) 156 (49.7) 0.83  156 (49.7) 0.60  160 (51.0) 0.75  166 (52.9) 0.29 
            
Gender            
  Male (213) 102 (47.9)   108 (50.7)   106 (49.8)   114 (53.5)  
  Female (226) 118 (52.2) 0.39  114 (50.4) 0.52  120 (53.1) 0.51  111 (49.1) 0.39 
            
Ethnicity            
  Chinese (390) 194 (49.7)   199 (51.0)   202 (51.8)   202 (51.8)  
  Non-Chinese (49) 26 (53.1) 0.76  23 (46.9) 0.65  24 (49.0) 0.76  23 (46.9) 0.55 
            
Grade            
  Well/Moderate (397) 198 (49.9)   196 (49.4)   202 (50.9)   204 (51.4)  
  Poor (42) 22 (52.4) 0.87  26 (61.9) 0.15  24 (57.1) 0.52  21 (50.0) 0.87 
            
Stage            
  I & II (213) 124 (58.2)   123 (57.7)   124 (58.2)   124 (58.2)  
  III & IV (226) 96 (42.5) <0.011  99 (43.8) <0.01  102 (45.1) <0.01  101 (44.7) <0.01 
            
Site            
  Proximal colon (161) 75 (46.6)   77 (47.8)   83 (51.6)   83 (51.6)  
  Distal colon & rectum (278) 145 (52.2) 0.28  145 (52.2) 0.43  143 (51.4) >0.99  142 (51.1) >0.99 
            
Tumour size            
  <5cm (263) 134 (51.0)   130 (49.4)   131 (49.8)   144 (54.8)  
  ≥5cm (176) 86 (48.9) 0.70  92 (52.3) 0.63  95 (54.0) 0.44  81 (46.0) 0.08 
            
Vascular invasion            
  Absent (389) 195 (50.1)   196 (50.4)   198 (50.9)   200 (51.4)  
  Present (50) 25 (50.0) >0.99  26 (52.0) 0.88  28 (56.0)  0.55  25 (50.0) 0.88 
            Lymphatic invasion            
  Absent (401) 199 (49.6)   202 (50.4)   205 (51.1)   205 (51.1)  
  Present (38) 21 (55.3) 0.61  20 (52.6) 0.87  21 (55.3) 0.74  20 (52.6) 0.87 
            
Perineural invasion 
Perineural invasion 
           
  Abs nt (418) 212 (50.7)   211 (50.5)   218 (52.2)   215 (51.4)  
  Present (21) 8 (38.1) 0.27  11 (52.4) >0.99  8 (38.1) 0.27  10 (47.6) 0.82 
            
Perforation            
  Absent (420) 212 (50.5)   214 (51.0)   218 (51.9)   220 (52.4)  
  Present (19) 8 (42.1) 0.49  8 (42.1) 0.49  8 (42.1) 0.49  5 (26.3) 0.03 
            
MSI            
  Absent (247) 124 (50.2)   117 (47.4)   117 (47.4)   127 (51.4)  
  Present (31) 16 (51.6) >0.99  21 (67.7) 0.04  23 (74.2) <0.01  20 (64.5) 0.19 
(50.2
) 
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6.2.2 Prognostic Significance of T-lymphocyte Subtype Density 
Univariate survival associations for the standard clinicopathological features and of 
T-lymphocyte subtype densities are shown in Table 4. To eliminate the confounding 
influence of chemotherapy on survival outcome, only the patients treated by surgery 
alone (n=300) were evaluated. As expected, the factors of advanced tumour stage, 
poor histological grade and tumour invasion into vascular, lymphatic and perineural 
spaces were each associated with poor survival (all P<0.01). In agreement with many 
previous studies (Ropponen et al. 1997; Naito et al. 1998; Guidoboni et al. 2001; 
Chiba et al. 2004; Menon et al. 2004; Prall et al. 2004; Pages et al. 2005; Galon et al. 
2006; Laghi et al. 2009; Roxburgh et al. 2009; Salama et al. 2009; Correale et al. 
2010; Deschoolmeester et al. 2010; Frey et al. 2010; Lee et al. 2010; Mlecnik et al. 
2011), tumours with high densities of CD3+ (P=0.02), CD8+ (P<0.01), 
CD8+GZMB+ (P<0.01) and FOXP3+ (P<0.01) cells were associated with 
significantly improved patient survival. In multivariate analysis, only tumour stage 
and histological grade were significantly associated with survival (Table 5). 
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Table 4. Univariate survival analysis for clinicopathological features and T-




CI: confidence intervals; HR: hazard risk ratio 
 
Feature HR 95% CI P 
    
Clinicopathological Features    
Gender (female vs male) 1.26 0.90-1.76 0.18 
Age (≥60 yrs vs <60 yrs) 1.35 0.86-2.11 0.19 
Ethnicity (Chinese vs non-Chinese) 1.11 0.63-1.96 0.72 
Stage (III & IV vs I & II) 5.11 3.60-7.26 <0.01 
Site (distal & rectal vs proximal) 0.96 0.68-1.36 0.82 
Tumour size (≥5 vs <5cm) 0.92 0.65-1.29 0.62 
Grade (poor vs well-moderate) 2.78 1.75-4.39 <0.01 
Vascular invasion (yes vs no) 2.40 1.42-4.07 <0.01 
Lymphatic invasion (yes vs no) 2.85 1.63-4.97 <0.01 
Perineural invasion (yes vs no) 2.56 1.35-4.89 <0.01 
Perforation (yes vs no) 1.74 0.88-3.41 0.11 
 
MSI status (MSI vs MSS) 0.78 0.34-1.78 0.55 
    
T-lymphocyte subtypes    
CD3+ (high vs low) 0.67 0.48-0.94 0.02 
CD8+ (high vs low) 0.58 0.42-0.81 <0.01 
CD8+GZMB+ (high vs low) 0.57 0.41-0.80 <0.01 
FOXP3+ (high vs low) 0.58 0.42-0.80 <0.01 
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Table 5. Multivariate survival analysis for clinicopathological features and T-
lymphocyte subtypes for patients treated with surgery alone. 
 
Feature HR 95% CI P 
    Stage (III & IV vs I & II) 4.29 2.95-6.25 <0.01 
Grade (poor vs well-moderate) 2.21 1.31-3.74 <0.01 
Vascular invasion (yes vs no) 1.34 0.77-2.32 0.31 
Lymphatic invasion (yes vs no) 1.23 0.64-2.35 0.54 
Perineural invasion (yes vs no) 1.43 0.72-2.81 0.30 
CD3+ (high vs low) 1.30 0.81-2.08 0.28 
CD8+ (high vs low) 0.67 0.37-1.21 0.18 
CD8+GZMB+ (high vs low) 0.93 0.51-1.71 0.82 
FOXP3+ (high vs low) 0.86 0.59-1.26 0.45 
    
 
CI: confidence intervals; HR: hazard risk ratio 
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6.3 Predictive Significance of T-lymphocyte Subtype Density 
Due to the irregular application of chemotherapy in stage II and IV patients, the 
predictive significance of clinicopathological features and of T-lymphocyte subtype 
densities was investigated in the stage III patient subgroup. Overall, patients treated 
with 5-FU chemotherapy showed significantly better survival compared to those 
treated by surgery alone (P<0.01, Table 6). Of the clinicopathological factors, 
significant differences in survival between 5-FU-treated and non-treated patients were 
observed for females, older patients and those with distal colon or rectal tumours (all 
P<0.01). A significantly better survival for 5-FU-treated compared to non-treated 
patients was also observed in subgroups of patients with well/moderate differentiated 
(P<0.01), poorly differentiated (P=0.03), and MSS (P=0.02) tumours. Patients with 
high densities of CD3+, CD8+ or CD8+GZMB+ cells had a significantly better 
survival if treated with chemotherapy compared to surgery alone (hazard ratio (HR) 
0.18, 0.26 and 0.26, respectively; each P<0.01). Patients with low densities of these 
cells treated with 5-FU also had a better survival than those without treatment, 
although to a lesser degree (HR 0.55, 0.51 and 0.51, respectively; P=0.11, 0.05 and 
0.06, respectively). The difference in the HRs between high and low density groups 
was significant for CD3+ T cells (P=0.032). Patients with high and low FOXP3+ cell 
densities treated with 5-FU had a better survival than those untreated to a similar 
degree (HR 0.41 and 0.43; P=0.11 and P=0.01, respectively). 
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Table 6. Predictive significance of clinicopathological features and of T-lymphocyte 
subtype densities in stage III CRC patients. 
 
Feature (N1, N2)* HR** 95% CI P P (ΔHR)# 
      
All cases (48, 71) 0.37 0.21-0.65 <0.01 >0.05 
     
Clinicopathological     
Gender: Male (22, 37) 0.63 0.27-1.46 0.28  
Gender: Female (26, 34) 0.24 0.11-0.53 <0.01 0.05 
Age<60 years (4, 36) 0.98 0.13-7.67 0.98  
Age≥60 years (44, 35) 0.42 0.22-0.80 <0.01 0.22 
Grade: Well & Moderate (41, 64) 0.42 0.23-0.76 <0.01  
Grade: Poor (7, 7) 0.13 0.02-0.78 0.03 0.12 
Tumour Site: Proximal (19, 29) 0.42 0.17-1.03 0.06  
Tumour Site: Distal & rectal (29, 42) 0.34 0.17-0.69 <0.01 0.36 
MSI: Absence (22, 39) 0.39 0.18-0.84 0.02  
MSI: Presence (5, 6)
a
 0.004 <0.001-6316.6 0.45 ND 
     
T-lymphocyte subtypes     
CD3+ High (20, 32) 0.18 0.07-0.46 <0.01  
CD3+ Low (28, 39) 0.55 0.27-1.14 0.11 0.03 
CD8+ High (18, 33) 0.26 0.10-0.68 <0.01  
CD8+ Low (30, 38) 0.51 0.26-1.00 0.05 0.13 
CD8+GZMB+ High (19, 37) 0.26 0.11-0.64 <0.01  
CD8+GZMB+ Low (29, 34) 0.51 0.25-1.03 0.06 0.12 
FOXP3+ High (17, 38) 0.41 0.14-1.23 0.11  
FOXP3+ Low (31, 33) 0.43 0.22-0.83 0.01 0.47 
     
 
*N1, number of patients treated with surgery alone; N2, number of patients treated 
with adjuvant 5-fluorouracil-based chemotherapy.  
**Hazard ratios for the survival of patients who received 5-fluorouracil-based 
chemotherapy compared to those treated by surgery alone.  
#
Comparisons of hazard ratio for all parameters. 
a
P value for hazard ratio difference is not determined due to low number of cases. 
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6.4 Discussion 
A large and growing body of evidence has established that high densities of TILS are 
prognostic for good outcome in human CRC (Ropponen et al. 1997; Naito et al. 
1998; Guidoboni et al. 2001; Chiba et al. 2004; Menon et al. 2004; Prall et al. 2004; 
Pages et al. 2005; Galon et al. 2006; Laghi et al. 2009; Roxburgh et al. 2009; Salama 
et al. 2009; Correale et al. 2010; Deschoolmeester et al. 2010 ; Frey et al. 2010; Lee 
et al. 2010 ; Mlecnik et al. 2011). These studies have demonstrated a role for the 
adaptive immune response in influencing the clinical behavior of CRC (Galon et al. 
2006), possibly by preventing the early stages of metastatic invasion (Pages et al. 
2005). The results of the present work confirm that high densities of tumour-
infiltrating T-lymphocyte subtypes are associated with early tumour stage (Table 3) 
and with better patient survival (Table 4). However, the major and novel finding of 
this study relates to the predictive significance of T-lymphocyte subtypes (Table 6). 
The current results expand upon earlier work on the predictive value of TILS in CRC 
(Morris et al. 2008; Halama et al. 2009) and breast cancer (Ladoire et al. 2008; 
Denkert et al. 2010) by investigating the predictive significance of different T-
lymphocyte subtypes. 
Similar to the results of Galon et al. (Galon et al. 2006), the densities of CD3+, CD8+ 
and CD8+GZMB+ cells were found to be significantly correlated (Figure 6). In 
agreement with Salama et al (Salama et al. 2009), positive correlations were also 
observed between the density of FOXP3+ immune cells and the other subtypes. It has 
been proposed that tumour-infiltrating FOXP3+ T regulatory cells in CRC are 
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indicative of homeostatic control of a robust immune response, rather than being 
merely immunosuppressive (Matera et al. 2010). This could explain why the density 
of FOXP3+ cells was positively associated with the densities of CD8+ and 
CD8+GZMB+ cytotoxic cells.  
Further evidence for the validity of our CRC cohort was derived from the observation 
that the pathological features of tumour cell invasion into vascular, lymphatic and 
perineural spaces were each associated with poor prognosis (Table 4). In addition, the 
better prognosis associated with high densities of the four immune cell subtypes 
investigated here (Table 5) concur with the results of many other studies (Ropponen 
et al. 1997; Naito et al. 1998; Guidoboni et al. 2001; Chiba et al. 2004; Menon et al. 
2004; Prall et al. 2004; Pages et al. 2005; Galon et al. 2006; Laghi et al. 2009; 
Roxburgh et al. 2009; Salama et al. 2009; Correale et al. 2010; Deschoolmeester et 
al. 2010; Frey et al. 2010; Lee et al. 2010). Although the T-lymphocyte subtype 
densities were not independent prognostic factors in the present series of CRC with 
mixed stage, these markers deserve further investigation in large, well characterized 
cohorts of early stage (node-negative) CRC. There is an urgent need for more 
accurate and robust prognostic markers in stage II CRC. This could be met by semi-
automated, quantitative evaluation of T-lymphocyte subtype density, possibly in 
combination with careful assessment of tumour cell invasion into lymphovascular and 
perineural spaces (Salama et al. 2009). 
By comparing the survival of stage III CRC patients treated with or without 5-FU-
based chemotherapy, the predictive significance of various factors including immune 
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cell densities were estimated. In agreement with several previous studies (Elsaleh et 
al. 2000; Morris et al. 2007; Dahl et al. 2009), the survival of patients treated with 5-
FU compared to those untreated was greater for female than male patients (HR=0.24, 
0.63 respectively, P<0.01, 0.28 respectively; Table 6). A significantly better survival 
for patients treated with chemotherapy was also seen for older patients and those with 
left-sided tumours. Patients with high densities of tumour-infiltrating CD3+, CD8+ 
and CD8+GZMB+ cells (HR=0.18, 0.26, 0.26, respectively; all P<0.01) had a better 
survival from 5-FU chemotherapy than patients with low densities (HR=0.55, 0.51, 
0.51, respectively, P=0.11, 0.05, 0.06, respectively), with the difference for CD3+ 
being significant (P=0.032). These results should be interpreted with caution because 
of the small sample sizes for several subgroups and the lack of randomization for 
chemotherapy. Nevertheless, they suggest that patients with high densities of TILS 
gain a greater survival advantage from 5-FU-based chemotherapy over those with low 
densities. This observation warrants further investigation in larger cohorts from 
randomized clinical trials of other cytotoxic and targeted treatment regimens. 
A potential confounder of interest to the prognostic and predictive significance of 
immune cell subtypes is MSI status, which has been associated with a higher degree 
of lymphocytic infiltration (Guidoboni et al. 2001; Prall et al. 2004; Salama et al. 
2009)., improved prognosis (Popat and Houlston 2005; Sinicrope et al. 2006) and a 
predictive significance (Barratt et al. 2002; Ribic et al. 2003; Carethers et al. 2004) in 
prior studies. Due to the incomplete availability of tumour blocks, only 287 cases 
could be examined for MSI status in this study. Some 31 (11%) tumours had MSI, 
which is a frequency similar to that observed in other East Asian CRC patient 
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series (Meng et al. 2007; Jeon et al. 2008). Also consistent with prior findings was 
the association between MSI and high CD8+ (P=0.04) and high CD8+GZMB+ 
(P<0.01) T cell densities (Guidoboni et al. 2001; Prall et al. 2004; Salama et al. 
2009), supporting the validity of the MSI analysis. However, MSI was not 
significantly associated with survival in untreated patients (Table 4), which is 
inconsistent with prior findings (Popat and Houlston 2005; Sinicrope et al. 2006). In 
the analysis of predictive significance, MSS patients treated with chemotherapy had a 
significantly better survival than those untreated (HR=0.39; p=0.02, Table 6), 
consistent with the findings of Carethers et al. (Carethers et al. 2004), However, the 
analysis of the predictive significance of MSI status could not be completed due the 
small sample size (n=11) of the MSI patients (Table 6). The only appropriate 
conclusion from these results may be that the initially small number of MSI cases 
(n=31), together with their further subgroup analysis preclude adequate assessment of 
prognostic (in untreated cases only), and predictive (in stage 3 cases according to 
treatment status) significance. 
The present study confirms and extends the results of Morris et al. (Morris et al. 
2008) who found that stage III CRC patients whose tumours showed a dense 
lymphocytic infiltrate, as determined from the pathology report, gained more survival 
advantage from adjuvant 5-FU chemotherapy than patients without this feature. It is 
presently unclear why CRC with a strong TIL reaction are apparently more 
responsive to 5-FU chemotherapy. One explanation may be that the release of soluble 
cytokines following chemotherapy-induced tumour cell death activates cytotoxic T-
lymphocytes (Lake and Robinson 2005; Zitvogel et al. 2008). In this case, it might 
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be expected that tumours showing evidence of a strong anti-tumour immune response 
prior to treatment would be more sensitive to chemotherapy. Recent work with an 
animal model suggests the anti-tumour effect of 5-FU could in part be mediated by its 
selective cytotoxic activity against myeloid-derived suppressor cells (MDSC) in the 
tumour bed (Vincent et al. 2010). MDSC are well known inhibitors of CD8+ T-
lymphocyte activation (Gabrilovich and Nagaraj 2009) and hence it would be 
interesting to quantify the prognostic and predictive values of MDSC cells in future 
work on CRC. 
 It was recently reported that a high density of tumour-infiltrating FOXP3+ immune 
cells correlated with good prognosis in colon cancer patients undergoing 
chemotherapy or chemo-immunotherapy (Correale et al. 2010). However, the lack of 
an arm without treatment in that study meant that it was impossible to estimate the 
predictive value of FOXP3+ cell density. The ratio of intraepithelial immune cells to 
total number of TILS staining for CD3, CD8 and GZMB was found to be predictive 
of response to chemotherapy in metastatic CRC (Halama et al. 2009), suggesting that 
immune cell localization as well as density may be important in determining chemo-
responsiveness. However, it was unclear from this study whether the individual T-
lymphocyte subtype densities alone were predictive of response. 
Two studies of neoadjuvant chemotherapy in human breast cancer have provided 
clear evidence of the predictive significance of tumour-infiltrating immune cells. In 
the first, the number of intra-tumoural lymphocytes in pretreatment breast tumours 
was a significant and independent predictor for complete pathological response; with 
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response rates of 40-42% and 3-7% for high and low cell density tumours, 
respectively (Denkert et al. 2010). The second study reported that complete 
pathological response correlated with a decreased number of tumour-infiltrating 
FOXP3+ cells (Ladoire et al. 2008). Treatment-related changes in the density of 
tumour-infiltrating T-lymphocyte subtypes and their predictive significance for 
pathological response could not be assessed in the current study of CRC treated with 
adjuvant chemotherapy. However, this would be an interesting area for further 
investigation in relation to the neoadjuvant treatment of rectal cancers. 
In conclusion, the results of our study confirm that high densities of tumour-
infiltrating CD3+, CD8+, CD8+GZMB+ and FOXP3+ cells are associated with good 
prognosis in CRC patients. Our results also suggest that patients with high densities 
of TILS; in particular CD3+ T cells, may have a better response to 5-FU-based 
chemotherapy compared to patients with low densities. Further work is required to 
elucidate the cellular mechanisms that link a strong TIL reaction to an apparently 
better response to cytotoxic chemotherapy.  
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7  INVESTIGATION OF T LYMPHOCYTE 
DENSITIES IN BLOOD AND TUMOURS, AND GENETIC 
BASIS 
7.1 Introduction 
Human tumours often contain infiltrates of immune cells such as T-lymphocytes, 
dendritic T cells and macrophages (Ohtani 2007). These lymphocytes are known as 
tumour-infiltrating lymphocytes (TILS) and have been associated with good 
prognosis in various cancers including CRC (Ropponen et al. 1997; Naito et al. 1998; 
Guidoboni et al. 2001; Chiba et al. 2004; Menon et al. 2004; Prall et al. 2004; Pages 
et al. 2005; Galon et al. 2006; Laghi et al. 2009; Roxburgh et al. 2009; Salama et al. 
2009; Correale et al. 2010; Deschoolmeester et al. 2010; Frey et al. 2010; Vincent et 
al. 2010; Mlecnik et al. 2011). TILS subtypes can be readily identified by distinctive 
cellular markers. These include CD4+ effector cells, CD8+ cytotoxic cells and their 
activated form with Granzyme B (GZMB) expression, CD45RO+ antigen sensitized 
cells and CD4+/CD25+/FOXP3+ regulatory cells (T4regs). Anti-tumour activity has 
been attributed to the first four cell types, whereas T4regs are postulated to exert a 
suppressive effect on these T cell activities (Clarke et al. 2006).  
TILS can cause T cell-mediated adaptive immune response which target tumour cells 
expressing tumour-associated antigens leading to inhibition of tumour growth and 
progression (Shankaran et al. 2001). Several studies have reported that elevated levels 
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of immune cells are observed in CRC patients in comparison with normal healthy 
donors (Clarke et al. 2006; Ling et al. 2007; Chaput et al. 2009). This has suggested 
that the activation of immune response is more likely to be systemic than simply 
localized in tumours. Ahmadzadeh et al. compared the functional and phenotypic 
characteristics of T4reg cells in tumours and blood of melanoma patients. The blood 
T4reg cells showed identical expression of surface markers as the tumour T4regs. 
When these cells were exposed to stimulants, both T4regs also responded in a similar 
way based on the detection of the cytokines produced, showing that the T4reg cells 
from blood and tissue are highly similar (Ahmadzadeh et al. 2008). Similar findings 
were also reported in CRC patients (Ling et al. 2007). The results of these studies 
show circulating immune cells share many similarities with intra-tumoural 
lymphocytes with respect to their phenotypic features and functions. However, it 
remains unclear if individuals with high concentrations of circulating T-lymphocytes 
are the individuals with a TILS phenotype.  
Evaluation of TILS subtype densities in three independent cohorts revealed that the 
intensity of the immune reaction at the tumour site can be a determinant of patients‟ 
clinical outcomes (Galon et al. 2006). Tumours with a strong adaptive immune 
reaction correlated with highly favorable prognosis whereas a low density of adaptive 
immune cells correlated with a very poor prognosis even in patients with minimal 
tumour invasion (Galon et al. 2007). However, the underlying mechanisms for the 
presence of high or low adaptive immune responses are unclear.  
Several SNPs (single nucleotide polymorphism) of T cell markers were reported to 
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have influence on the levels of their corresponding T cell subtypes (Table 7). The 
presence of the SNP ss46531523 in the perforin gene was correlated with fewer 
perforin+ cells among circulating CD8+ CTL (McIlroy et al. 2006). Three SNPs 
found in the promoter region of FOXP3 were associated with primary biliary 
cirrhosis, which may imply an inadequate Treg function in suppressing the 
autoimmune response to the liver causing bile duct destruction (Hanel et al. 2011). 
Furthermore, a non-synonymous SNP (55Q/Q) in GZMB was also reported to be 
associated with increased in-vitro expression of Granzyme B (Girnita et al. 2009). 
These findings suggest that the intensity of an individual‟s immune response could be 
an early manifestation of genetic differences.  
The objectives in this project are as follows: (1) to characterize the correlation 
between the densities of T cell subtypes in the peripheral blood and primary tumours 
of CRC patients; (2) to examine the correlation between genetic variants in CD8a, 
GZMB, FOXP3 and blood and tumour T cell densities.  
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Table 7. Overview of Studies on SNP Analysis in T Cell Representative Markers. 
Gene Sample SNPs Outcome References 
     
Perforin 14 CTL cell lines 
generated from HIV+ 
patients 
 63 A/G (ss46531524) 
 112 A/G (rs10999428) 
 1012 C/T (ss46531523) 
 The presence of the 1012T genotype correlated 
with fewer perforin+ cells among circulating CD8+ 
CTL. 
Mcllroy et al. 2006 
     
GZMB 396 pediatric heart 
transplant ; recipients 
52 healthy controls 
 55 Q/R (rs 8192917)  
 -295 A/G (rs 7144366) 
 55 Q/Q genotype is associated with increased in 
vitro expression of Granzyme B. 
Girnita et al. 2009 
     
FOXP3 Luciferase assays  -794 C/G (ss270137548) 
 -738 C/T (rs11091253) 
 -540 C/T (ss270137549) 
 construct −794 C/G showed a significant increased 
activity than major allele. 
 
 promoter variant with two SNPs −738 C/T and 
−540 C/T displayed a significantly higher activity 
compared with major allele. 
Hanel et al. 2011  
     
FOXP3 120 SLE patients; 160 
matched controls 
 -2383 C/T (rs 3761549)                                                                                                                                                                                                                                                                                
 -3281 C/A (rs 3761548) 
 -2383T/-3281A allele was associated with increased 
risk of SLE. 
Lan et al. 2010
     
FOXP3 93 Crohn‟s diseases; 82 
with primary biliary 
cirrhosis (PBC). 
 -605 4 -/ATT (rs590234) 
 -3279 A/C (rs3761548) 
 -924 A/G (rs2232364) 
 IVS9+459 T/C (rs2280883) 
 IVS9+459 associated with risk of primary biliary 
cirrhosis. 
Park et al. 2005 
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7.2 Results 
7.2.1 Correlation of T Cell Subtype Densities in Blood and Tumour of CRC 
Patients  
Mononuclear cells extracted from 41 CRC patients‟ peripheral blood were stained 
with antibodies of T cell markers and analyzed by flow cytometry. Cells with 
identical size and complexity were gated and further sorted based on the expression of 
CD3. T4reg and activated cytotoxic T cells were recognized as CD4+FOXP3+ and 
CD8+GZMB+ cells, respectively (Figure 7). The distribution of the levels of 
circulating T cell subtypes is shown in Figure 8.  The median values of CD8+, 
CD8+GZMB+ and CD4+FOXP3+ T cells were 32% (15%-66%), 14% (2%-61%) and 
3% (0.04%-9%).  
A total of 41 matched tumours were also stained with the same T cell markers as 
above by IHC (Figure 9). The number of positively stained lymphocytes was counted 
manually for each regions and the density of lymphocytes for each tumour was then 
expressed as cells per square millimeter. Median densities of intra-tumoural 









respectively (Figure 8 D-F).  
Figure 10 shows the densities of CD8+, CD8+GZMB+ and CD4+FOXP3+ T cells in 
tumours were correlated with the levels of their circulating counterparts significantly. 
(Pearson correlation coefficients r=0.38, r=0.33 and r=0.28, respectively, all P<0.05)  











Figure 7. Gating strategies for activated cytotoxic T cells (A) and T4regs (B) using 
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Figure 8. Density of T-lymphocyte subtypes, including CD8+ T cells (A, D), 
CD8+GZMB+ T cells (B, E) and CD4+FOXP3+ T cells (C, F) observed in 41 paired 
blood and tumours from CRC patients 
A B 
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Figure 9. Immunohistochemical stains for CD3 (A), double staining of CD8 and 
GZMB (B) as well as CD4 and FOXP3 T cells (C) in the same region of a CRC 
tumour at 100x magnification. Panel below are enlarged images for the black circle 
regions taken at 400x magnification. The black arrows highlight activated cytotoxic T 
cells with coexpression of CD8 (red) and GZMB (brown) (E) and T4reg cells with co-
expression of CD4 (red) and FOXP3 (brown) (F). The white arrows indicate cytotoxic 
T cells with no GZMB expression (E) and CD4 T helper cells (F). 
Brown and red stains were achieved by incubation with DAB and alkaline 
phosphatase red respectively; and the nuclei were counterstained with haematoxylin. 
 
D E F 
A B C 
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7.2.2 Correlation of Gene Expression of T Cell Markers with Their 
Corresponding T Cell Subtype Levels in Peripheral Blood 
The relative gene expression level of CD8a showed strong correlation with the 
proportion of CD8+ T cell in peripheral blood (r=0.48, P<0.01). However, there was 
no significant correlation between gene expression levels and their corresponding 
blood T cell densities for GZMB (r=0.17, P=0.30) and FOXP3 (r=0.19, P=0.22),  
(Figure 11). 
 
Figure 10. Correlation between densities of intra-tumoural and circulating CD8+ T 




Figure 11. Correlation between gene expression levels of T cell markers: CD8a (A) 
GZMB (B) and FOXP3 (C) and their corresponding circulating T-lymphocyte subtype 
levels.  
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7.2.3 Correlation of Genotypes with Densities of Intra-tumoural and Levels of 
Circulating T Cell Subtypes 
Twelve SNPs from CD8a, 22 from GZMB and 9 from FOXP3 were genotyped in 41 
CRC patients with blood and tissue densities. The other nine cases were unable to be 
genotyped due to sample exhaustion. The minor allele frequency (MAF) of these 
SNPs showed ≥1% in Asian cohorts from dbSNP database (Table 8). The SNPs 
genotype distributions reported in our study were compared to those of Han Chinese 
and Japanese cohorts by Chi-square test (Table 9). The majority of distributions were 
similar between series with differences only observed in 10/39 (25%) of genotypes 
(Table 9).  
Table 10 shows that a total of 11 SNPs from GZMB and FOXP3 were found 
associated with their respective T cell subtype densities in blood (all P<0.05). GZMB 
SNP rs#8192922, and two SNPs from FOXP3 (rs#3761549 and rs#3761547) were 
significantly associated with their tumour T cell subtype densities (P=0.01, 0.02 and 
0.02, respectively). SNP #rs8192922 was the only SNP associated with the 
CD8+GZMB+ cell densities significantly in tissue and blood (both P=0.01). As 
shown in Figure 12, higher densities of circulating and intra-tumoural CD8+GZMB+ 
cells were seen in the patients with genotype GG compared to GA carriers. There 
were no AA individuals observed in this study.  
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Amino Acid  
Change 
 
Allelic Frequency in  
Chinese/Asian 
       
CD8a rs2944254 G>A Intron 5  G:0.84 A:0.16 
CD8a rs2367377 A>C Near 3‟ UTR  A:0.91 C:0.09 
CD8a rs1515950 G>A 5‟ UTR  G:0.84 A:0.16 
CD8a rs3020729 T>C Exon 6 Non coding T:0.84 C:0.16 
CD8a rs6743139 G>A 5‟ UTR  G:0.93 A:0.07 
CD8a rs3810831 A>G 5‟ UTR  A:0.92 G:0.08 
CD8a rs6718678 C>T Near 3‟ UTR  C:0.79 T:0.21 
CD8a rs938487 T>C Near 3‟ UTR  T:0.81 C:0.19 
CD8a rs2367376 A>G Near 3‟ UTR  T:0.81 C:0.19 
CD8a rs1051386 T>C Exon 6 Non coding T:0.85 C:0.15 
GZMB rs8192920 G>T Near 3‟ UTR  G:0.87 T:0.13 
GZMB rs2273844 G>A Exon 1 Non coding G:0.68 A:0.32 
GZMB rs1957528 T>C 5‟ UTR  T:0.75 C:0.25 
GZMB rs8012137 A>G Near 3‟ UTR  A:0.57 G:0.43 
GZMB rs7141106 A>T 5‟ UTR  A:0.51 T:0.49 
GZMB rs1957527 A>T 5‟ UTR  A:0.72 T:0.28 
GZMB rs8192916 T>C 5‟ UTR  T:0.52 C:0.48 
GZMB rs6573910 C>T Intron 4  C:0.68 T:0.32 
GZMB rs6573913 A>T 5‟ UTR  A:0.72 T:0.28 
GZMB rs8192919 C>T Near 3‟ UTR  C:0.91 T:0.09 
GZMB rs7144366 C>T 5‟ UTR  C:0.57 T:0.43 
GZMB rs2236338 A>G Exon 5 Try→His A:0.67 G:0.33 
GZMB rs8192922 G>A Near 3‟ UTR  G:0.82 A:0.18 
GZMB rs10909625 A>G Exon 3 Lys→Lys A:0.67 G:0.33 
GZMB rs6573912 T>C 5‟ UTR  T:0.75 C:0.25 
GZMB rs9671454 C>G Intron 2  C:0.99 G:0.01 
GZMB rs8192917 A>G Exon 2 Arg→Gln A:0.68 G:0.32 
GZMB rs8016685 T>A Near 3‟ UTR  T:0.57 A:0.43 
GZMB rs2236337 T>C Exon 5 Non coding T:0.66 C:0.34 
GZMB rs762085 A>T Near 3‟ UTR  A:0.57 T:0.43 
GZMB rs6573911 C>T Intron 4  C:0.67 T:0.33 
GZMB rs10873219 G>T Intron 2  G:0.82 T:0.18 
FOXP3 rs3761549 C>T Intron 1  C:0.77 T:0.23 
FOXP3 rs2280883 T>C Intron 10  T:0.79 C:0.21 
FOXP3 rs11091253 C>T 5‟ UTR  C:0.99 T:0.05 
FOXP3 rs3761547 A>G Intron 1  A:0.77 G:0.23 
FOXP3 rs3761548 A>C Intron 1  A:0.80 C:0.20 
FOXP3 rs2232365 A>G Intron 1  A:0.57 G:0.43 
FOXP3 rs12843496 C>T Intron 1  C:0.99 T:0.01 
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Table 9. Comparison of SNP frequencies between the NUH cohort and other Asian cohorts. 




 NUH Cohort P value 
AA*(%) AB*(%) BB*(%) AA*(%) AB*(%) BB*(%) 
          
CD8a rs2944254 G>A 56 (68) 26 (32) 0 (0) 11 (27) 29 (71) 1 (2) <0.01 
CD8a rs2367377 A>C 78 (91) 0 (0) 8 (9) 36 (88) 5 (12) 0 (0) <0.01 
CD8a rs1515950 G>A 72 (84) 0 (0) 14 (16) 33 (89) 3 (8) 1 (3) <0.01 
CD8a rs3020729 T>C 58 (69) 26 (31) 0 (0) 27 (66) 11 (27) 3 (7) 0.04 
CD8a rs6743139 G>A 74 (86) 12 (14) 0 (0) 34 (83) 6 (15) 1 (2) 0.34 
CD8a rs3810831 A>G 72 (84) 14 (16) 0 (0) 25 (81) 5 (16) 1 (3) 0.25 
CD8a rs6718678 C>T 50 (58) 36 (42) 0 (0) 23 (56) 12 (29) 6 (15) <0.01 
CD8a rs938487 T>C 56 (65) 28 (33) 2 (2) 24 (59) 12 (29) 5 (12) 0.08 
CD8a rs2367376 A>G 59 (65) 30 (33) 2 (2) 24 (59) 12 (29) 5 (12) 0.06 
CD8a rs1051386 T>C 60 (70) 26 (30) 0 (0) 16 (52) 8 (26) 7 (23) <0.01 
GZMB rs8192920 G>T 66 (77) 18 (21) 2 (2) 25 (61) 13 (32) 3 (7) 0.13 
GZMB rs2273844 G>A 42 (49) 34 (39) 10 (12) 20 (49) 16 (39) 5 (12) 1.00 
GZMB rs1957528 T>C 48 (57) 30 (36) 6 (7) 19 (46) 18 (44) 4 (10) 0.52 
GZMB rs8012137 A>G 34 (38) 34 (38) 22 (24) 12 (44) 11 (41) 4 (15) 0.56 
GZMB rs7141106 A>T 28 (31) 36 (40) 26 (29) 7 (17) 19 (46) 15 (37) 0.24 
GZMB rs1957527 A>T 48 (53) 34 (38) 8 (9) 19 (46) 18 (44) 4 (10) 0.76 
GZMB rs8192916 T>C 24 (28) 42 (49) 20 (23) 6 (15) 18 (45) 16 (40) 0.10 
GZMB rs6573910 C>T 42 (49) 34 (39) 10 (12) 20 (49) 15 (37) 6 (15) 0.88 
GZMB rs6573913 A>T 48 (53) 34 (38) 8 (9) 20 (50) 16 (40) 4 (10) 0.94 
GZMB rs8192919 C>T 40 (83) 8 (17) 0 (0) 26 (63) 13 (32) 2 (5) 0.06 
GZMB rs7144366 C>T 26 (30) 46 (54) 14 (16) 13 (32) 22 (54) 6 (15) 0.97 
GZMB rs2236338 A>G 40 (46) 36 (42) 10 (12 20 (50) 14 (35) 6 (15) 0.73 
GZMB rs8192922 G>A 62 (70) 22 (25) 4 (5) 36 (88) 5 (12) 0 (0) 0.08 
GZMB rs10909625 A>G 42 (47) 36 (40) 12 (13) 20 (49) 15 (37) 6 (15) 0.93 
GZMB rs6573912 T>C 48 (57) 30 (36) 6 (7) 20 (49) 17 (41) 4 (10) 0.66 
GZMB rs9671454 C>G 86 (98) 2 (2) 0 (0) 4 (10) 15 (37) 22 (54) <0.01 
GZMB rs8192917 A>G 42 (49) 34 (39) 10 (12) 0 (0) 18 (45) 22 (55) <0.01 
GZMB rs8016685 T>A 34 (38) 34 (38) 22 (24) 14 (34) 20 (49) 7 (17) 0.45 
GZMB rs2236337 T>C 41 (45) 38 (42) 12 (13) 20 (49) 15 (37) 6 (15) 0.85 
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GZMB rs762085 A>T 34 (38) 34 (38) 22 (24) 17 (41) 17 (41) 7 (17) 0.64 
GZMB rs6573911 C>T 42 (47) 36 (40) 12 (13) 20 (49) 15 (37) 6 (15) 0.93 
GZMB rs10873219 G>T 60 (70) 22 (25) 4 (5) 22 (54) 15 (37) 4 (10) 0.18 
FOXP3 rs3761549 C>T 60 (70) 12 (14) 14 (16) 22 (76) 2 (7) 5 (17) 0.60 
FOXP3 rs2280883 T>C 58 (71) 14 (17) 10 (12) 32 (78) 5 (12) 4 (10) 0.68 
FOXP3 rs11091253 C>T 170 (99) 2 (1) 0 (0) 38 (93) 2 (5) 1 (2) 0.03 
FOXP3 rs3761547 A>G 60 (70) 12 (14) 14 (16) 0 (0) 32 (80) 8 (20) <0.01 
FOXP3 rs3761548 A>C 60 (70) 18 (21) 8 (9) 32 (78) 5 (12) 4 (10) 0.49 
FOXP3 rs2232365 A>G 42 (49) 14 (16) 30 (35) 21 (51) 7 (17) 13 (32) 0.94 
FOXP3 rs12843496 C>T 168 (99) 0 (0) 2 (1) 41 (100) 0 (0) 0 (0) 0.49 
          
 
*A: Major allele, B: Minor allele 
#
Han Chinese and Japanese cohorts 
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Table 10. Correlations of T cell marker SNP frequencies with T cell subtype densities 
in blood and tissue 
     
Gene SNP ID Nucleotide 
change 
Blood (Proportion)* Tissue 
(Density)* 
     
CD8a rs2944254 G>A 0.48 0.10 
CD8a rs2367377 A>C 0.59 0.59 
CD8a rs1515950 G>A 0.37 0.05 
 CD8a rs3020729 T>C 0.80 0.35 
CD8a rs6743139 G>A 0.51 0.34 
CD8a rs3810831 A>G 0.12 0.44 
CD8a rs6718678 C>T 0.60 0.30 
CD8a rs938487 T>C 0.20 0.71 
CD8a rs2367376 A>G 0.28 0.71 
CD8a rs1051386 T>C 0.95 0.25 
GZMB rs8192920 G>T 0.09 0.81 
GZMB rs2273844 G>A 0.02 0.22 
GZMB rs1957528 T>C 0.10 0.88 
GZMB rs8012137 A>G 0.57 0.77 
GZMB rs7141106 A>T 0.02 0.36 
GZMB rs1957527 A>T 0.10 0.88 
GZMB rs8192916 T>C 0.04 0.39 
GZMB rs6573910 C>T 0.01 0.21 
GZMB rs6573913 A>T 0.13 1.00 
GZMB rs8192919 C>T 0.23 0.90 
GZMB rs7144366 C>T 0.69 0.65 
GZMB rs2236338 A>G 0.01 0.16 
GZMB rs8192922 G>A 0.01 0.01 
GZMB rs10909625 A>G 0.01 0.21 
GZMB rs6573912 T>C 0.19 0.98 
GZMB rs9671454 C>G 0.04 0.52 
GZMB rs8192917 A>G 1.00 0.34 
GZMB rs8016685 T>A 0.45 0.45 
GZMB rs2236337 T>C 0.01 0.21 
GZMB rs762085 A>T 0.39 0.49 
GZMB rs6573911 C>T 0.01 0.21 
GZMB rs10873219 G>T 0.04 0.52 
FOXP3 rs3761549 C>T 0.61 0.02 
FOXP3 rs2280883 T>C 0.51 0.86 
FOXP3 rs11091253 C>T 0.12 0.13 
FOXP3 rs3761547 A>G 0.34 0.02 
FOXP3 rs3761548 A>C 0.51 0.86 
FOXP3 rs2232365 A>G 0.02 0.20 
FOXP3 rs12843496 C>T NA NA 
     
 
*P value of likelihood ratio 
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Figure 12. Densities of CD8+GZMB+ T lymphocytes in blood (A) and tumour (B) 
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7.3 Discussion 
To our knowledge, this is the first study to report on correlations between matched 
densities of intra-tumoural and circulating T cell subtypes in CRC patients. Our 
results indicated that individuals with high concentrations of various circulating T cell 
subtypes may have increased intra-tumoural T cell densities (Figure 10). In vitro 
assays performed by Maccalli et al. have shown that reduced cytotoxicity of 
peripheral blood cells may be due to down-regulated expression of cytotoxic 
molecules (perforin, granzymeB and FasL) in patients with cancer (Maccalli et al. 
2008). These findings suggest that the presence of immune cell subsets in blood 
correlate with their counterparts in tumour sites as a consequence of a global anti-
tumour immune response in the host.  
The prognostic and predictive values of TILS subtypes in CRC described in Chapter 
3, implied that their circulating counterparts may be useful for predicting the clinical 
outcome of this disease. In the phase II trial of GOLFIG-1 chemoimmunotherapy 
(combination of gemcitabine, oxaliplatin, levofolinic acid, 5-fluorouracil, granulocyte 
macrophage colony-stimulating factor and interleukin 2), CRC patients who had an 
increase in CTLs, memory T cells and depletion of T4regs had a prolonged time to 
disease progression and overall survival (Correale et al. 2008). This implied that the 
evaluation of circulating T cell subtypes may represent a less invasive method to use 
to predict prognosis and possibly also the response to treatment. However, further 
validation by testing the association of patient survival and chemotherapy response 
with blood cell levels is required in order to support the notion above.    
Gene expression level of CD8a correlated significantly (r=0.48, P<0.01) with CD8+ 
T cells density in the blood. However, no significant correlations were found for both 
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GZMB and FOXP3 genes. Protein is the downstream product of mRNA, so one might 
assume that there should be some degree of correlation between the mRNA and 
protein (Greenbaum et al. 2003). One of the earliest analyses of correlation was 
performed on 19 proteins in the human liver. A positive correlation of 0.48 was 
reported by Anderson and Seilhamer (Anderson and Seilhamer 1997). Orntoft et al. 
found highly significant correlations in human carcinomas when looking at the 
changes in mRNA and protein expression level (Orntoft et al. 2002). In contrast, 
another two studies on prostate and lung cancers reported either no significant 
correlation, or that a significant correlation is only found in a small subset of the 
proteins (Chen et al. 2002; Lichtinghagen et al. 2002). Therefore, the relationship 
between mRNA and protein expression is still debatable. There are several other 
possible reasons for the poor correlations reported for GZMB and FOXP3 in our 
cohort. Firstly, GZMB and FOXP3 are not expressed exclusively in CD8+ and CD4+ 
T cells. GZMB have also been found to be expressed in other immune cells as well as 
in normal cells of non-haematopoietic origin such as chodrocytes, keratinocytes, type 
II pneumocyte, Sertoli cells, primary spermatocytes, cells of granulose and 
syncytiotrophoblast (Rousalova and Krepela). A small population of CD8+ cells was 
also identified as FOXP3+ in CRC patients‟ blood (Chaput et al. 2009). Secondly, the 
involvement of complicated and varied post-transcriptional mechanisms during 
translation could also account for a lack of correlation (reviewed in (Mansfield and 
Keene 2009)). In addition, protein may differ substantially in their in vivo half lives, 
affecting their accurate measurement (Glickman and Ciechanover 2002). 
A high concordance in the distribution of SNPs genotypes was observed between our 
cohort and other East Asia populations (Table 9). However, 26% of the SNPs showed 
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significant differences. The majority of our cohort was Chinese (80%) and they are 
descendants mainly from Southern provinces of China. Although they might share 
common ancestral backgrounds with the northern Han Chinese in China, these two 
populations are genetically varied to some extent due to geographically distinct origin 
(Teo et al. 2009). Another possibility for the differences observed could also be due to 
analytical methods used for SNPs detection.  
Among the 39 SNPs that have examined, GZMB SNP #rs8192922 was significantly 
associated with the density of CD8+GZMB+ T cells in both tissue and blood of CRC 
patients. This SNP is located downstream of GZMB gene transcription end site which 
is 403 base pairs away and seems to be under a selection pressure, since it is highly 
conserved across species including gorilla, orangutan, rhesus, marmoset, cow and dog 
(Figure 13). A highly conserved sequence is more likely to carry with it an important 
biological role (Levy et al. 2001). Regions of conserved non-coding sequence, 
identified by using comparative sequence analysis methods between mouse and 
human genomic sequences, were reported to play a role in transcriptional regulation. 
These suggest that GZMB SNP #rs8192922 may be localized at the distal enhancer 
region which could possibly influence transcription efficiency of GZMB gene (Birney 
et al. 2007).  
In summary, we found positive correlations between the levels of circulating T cell 
subtypes with the densities of their corresponding intra-tumoural T cell subtype. The 
mRNA expression of CD8a but not GZMB and FOXP3 correlated with the density of 
their respective cells. The SNP analysis revealed that CRC patients with GG genotype 
of GZMB SNP #rs8192922 have a higher density of CD8+GZMB+ cells than those 
with the GA genotype. However, the underlying mechanisms for the effect of the SNP 
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on CD8+GZMB+ T cell densities are unclear. Our data suggest that SNPs could be 
potential factors to determine host immune response in tumours.  
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Figure 13. Evolutionary conservation of the GZMB gene (transcribed right to left from the transcription start site indicated at the bottom 
of the figure). The SNP rs8192922 (indicated by red arrow) is located in a highly conserved region between species. 
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8 CONCLUSIONS AND FUTURE DIRECTIONS 
A minority of colorectal tumours are characterized by the presence of high densities 
of infiltrating lymphocytes. These have consistently been associated with good patient 
outcome, with some authors suggesting their prognostic significance can rival or even 
surpass that of the TNM staging system (Galon et al. 2006; Galon et al. 2007; 
Mlecnik et al. 2011). The present results confirm the prognostic value of various 
tumour-infiltrating T cell subtype densities in colorectal cancer, but also suggest they 
have predictive significance for the response to 5-FU-based chemotherapy. High 
densities of CD3+, CD8+ and CD8+GZMB+ cells were associated with better 
survival following adjuvant treatment compared to low densities of these markers. 
Our findings suggest that immune cell subtype densities should be investigated further 
as potentially useful clinical biomarkers for response to cytotoxic chemotherapy.     
In Chapter 4, we observed positive correlations between the levels of circulating T 
cell subtypes and the densities of their corresponding intra-tumoural T cells in CRC 
patients. Taken together, our findings suggest that anti-tumour reactions may not be 
occurring in tumours only but may be a reflection of a more global immune response. 
Based on this, we hypothesized that varied intensities of systemic anti-tumour 
immune response observed in CRC patients could be due to genetic variations in 
genes encoding immune cell markers. The SNPs analysis on T cell markers showed 
that CRC patients with GG genotype of GZMB SNP rs8192922 have higher density of 
CD8+GZMB+ cells than those with GA. Further investigation is needed to ascertain 
the functional significance of GZMB SNP rs8192922. 
In summary, our study has confirmed the prognostic and predictive significance of 
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TILS subtypes. The findings are anticipated to provide new insights on identifying 
reliable and potential markers that can be included for clinical practice in the future. 
The assessment of T cell subtypes in blood and tumour also supports the notion that 
the anti-tumour reaction in CRC patients is a systemic host response. Varied 
intensities of systemic anti-tumour immune response could be a consequence of 
polymorphisms that occur in the immune cell genes. Taken together, the results 
suggest less invasive genetic and/or peripheral blood monitoring of TILS, and 
consequent prognostication and prediction of 5-FU response in CRC patients, could 
be feasible. Future work to validate these findings is required. 
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